<p>Calman A. MacLennan of Novartis Vaccines Institute for Global Health in Italy will develop a technology platform for the production of highly immunogenic and affordable polysaccharide vaccines. The platform will produce bacterial polysaccharides linked to outermembrane GMMA particles, rather than to carrier proteins, that will act as adjuvants for an enhanced antibody response.</p>


Calman A. MacLennan of Novartis Vaccines Institute for Global Health in Italy will develop a technology platform for the production of highly immunogenic and affordable polysaccharide vaccines. The platform will produce bacterial polysaccharides linked to outermembrane GMMA particles, rather than to carrier proteins, that will act as adjuvants for an enhanced antibody response.